Simris Group: Lonza partnership brings ADC platform license deal closer - Emergers

The strategic partnership with Lonza puts Simris in a stronger position going forward as it both validates Simris IP in the high value Antibody-Drug Conjugate (ADC) space and moves the company closer to licensing deals, where we see opportunities for large revenues even in the short term. Encouraged by the deal, we continue to find support for a fair value of SEK 170-230m, which translates to SEK 0.94-1.28 per share in 12-24 months.

Länk till analysen i sin helhet: https://www.emergers.se/simris_q/